RecruitingEarly Phase 1NCT05773326

Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

Studying Glial tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nader Sanai
Principal Investigator
Nader Sanai, MD, MD
Chief Scientific Officer/Director
Intervention
Temsirolimus(drug)
Enrollment
12 target
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (1)

Collaborators

Barrow Neurological Institute · Ivy Brain Tumor Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05773326 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor

← Back to all trials